Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Data ReadoutpositiveCAD-1005Positive

AI Analysis

Summary

Cadrenal Therapeutics presented late-breaking Phase 2 data for CAD-1005, its first-in-class 12-LOX inhibitor, showing greater than 25% reduction in thrombotic events in heparin-induced thrombocytopenia at the ISTH 2026 Congress.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Greater than 25% reduction in thrombotic events in HIT

Importance:7/10

Sentiment:

0.80

Phase 2 datafirst-in-class12-LOX inhibitorthrombotic eventslate-breaking dataISTH 2026

Related Companies

$CVKD

Read the original article

Published by yahoo_finance on July 13, 2026 1:00 PM

Read Original